GlassScriptPhysician profile
Amy M Ethridge
NPI 1578022109
$2,275.43
in general payments reported to CMS, 2019-2025
36 companies · $950 in 2025
The $950 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.69 · 2022: $113 · 2023: $257 · 2024: $915 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.98 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $380.71 | 2023-2025 | |
| Janssen Biotech, INC. | $183.77 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Abbvie INC. | $167.26 | 2024-2025 | |
| Tempus Ai, INC | $158.24 | 2024 | Xt Cdx |
| Merck Sharp & Dohme LLC | $151.45 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $136.50 | 2023-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $112.40 | 2024-2025 | Tagrisso, Imfinzi |
| Seagen INC. | $99.99 | 2025 | |
| Pfizer INC. | $89.75 | 2025 | |
| Gilead Sciences, INC. | $76.01 | 2024-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $75.07 | 2023-2025 | Libtayo |
| Glaxosmithkline, LLC. | $49.47 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Sobi, INC | $46.32 | 2024-2025 | |
| Pharmaessentia USA Corporation | $44.48 | 2024-2025 | Besremi |
| Genzyme Corporation | $38.57 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.52 | 2025 | Tecentriq |
| Geron Corporation | $34.45 | 2025 | Rytelo |
| Dendreon Pharmaceuticals LLC | $33.62 | 2022 | |
| Myriad Genetic Laboratories, INC. | $32.16 | 2022 | |
| Lilly USA, LLC | $28.90 | 2024 | Verzenio, Jaypirca |
| Amgen INC. | $27.00 | 2021-2023 | Kyprolis |
| Coherus Oncology, INC. | $26.78 | 2024 | |
| Tersera Therapeutics LLC | $24.21 | 2024 | Zoladex |
| Eisai INC. | $23.70 | 2024 | |
| Sun Pharmaceutical Industries INC. | $21.25 | 2024 | |
| Astellas Pharma US INC | $21.05 | 2024 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $20.25 | 2025 | Iclusig |
| Genmab U.S., INC. | $19.91 | 2025 | Tivdak |
| Accord Healthcare, INC. | $16.93 | 2025 | |
| Kyowa Kirin, INC. | $16.92 | 2024 | Poteligeo |
| Celgene Corporation | $15.10 | 2025 | Reblozyl |
| Array Biopharma INC | $14.82 | 2025 | Braftovi, Lorbrena, Mektovi |
| Adaptive Biotechnologies Corporation | $14.58 | 2025 | Clonoseq |
| Exelixis INC. | $14.23 | 2025 | Cabometyx |
| Novocure INC. | $13.23 | 2021 | |
| Daiichi Sankyo INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ethridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.